Search Bar & Filters
Found 8 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the safety, tolerability, pharmacokinetics PK, and immune response of a drug called SV001 in patients with idiopathic pulmonary fibrosis IPF, a lung condition. This Phase IIa clinical trial is randomized, double-blind, and placebo-controlled, aiming to gather detailed information about how the drug behaves in the body and its safety profile. Participants will receive multiple doses of SV001 or a placebo, with the study designed to compare these groups. The treatment period includes escalating doses to assess how the drug is tolerated and processed by the body. The study will last approximately one year, during which participants will be closely monitored. During the trial, participants will undergo regular assessments including checking for treatment-related adverse events, measuring the drug concentration in blood over time, and testing for immune responses. The main outcome is the incidence of adverse events over about one year. Additional evaluations will look at peak drug levels, time to peak levels, drug exposure over time, half-life, and immunogenicity. Safety and tolerability will be continuously monitored throughout the study period.
Actively Recruiting
Researchers are evaluating 9MW1911 in adults aged 40 to 75 who have been diagnosed with Chronic Obstructive Pulmonary Disease COPD for at least one year. This Phase II clinical trial is designed to assess how well 9MW1911 works and how safe it is for treating COPD. The study compares two different doses of 9MW1911 given intravenously with a placebo, and aims to better understand treatment effects on COPD flare-ups and lung function. Participants receive intravenous infusions of either 9MW1911 in one of two dose levels or a placebo every 28 days. Each treatment group includes 120 patients, all receiving stable standard care for COPD. The study lasts for 52 weeks of treatment, followed by safety and immune response monitoring up to 60 weeks. Researchers measure lung function, COPD exacerbations, quality of life, and other health markers during this period. During the study, participants will have regular visits for lung function tests, questionnaires about COPD symptoms and quality of life, blood tests, and safety assessments. These assessments occur at multiple time points, such as weeks 0, 4, 8, 12, 24, 36, and 52. The main outcome is the rate of moderate to severe COPD exacerbations over one year. Additional measures include lung function changes, time to first exacerbation, and biological markers. Safety and tolerability are followed for up to 60 weeks to ensure participant well-being throughout the trial.
Actively Recruiting
Stroke is one of the leading causes of death worldwide, with ischemic stroke being the most common type. Researchers are evaluating whether early administration of oral aspirin after intravenous thrombolysis improves functional outcomes for patients with acute ischemic stroke. The study aims to determine if starting aspirin treatment within 3 hours of thrombolysis can prevent neurological deterioration without increasing bleeding risks. Participants are randomly assigned to one of two groups the interventional group receives 300 mg of oral aspirin shortly after starting intravenous thrombolysis, while the control group receives a placebo. Both groups receive the best standard medical care according to current guidelines. Aspirin tablets may be chewed or given via a nasogastric tube if swallowing is difficult. The treatment is administered within 3 hours of initiating thrombolysis. During the study, participants are monitored for neurological improvements and potential complications using scales like the modified Rankin scale and NIH Stroke Scale at various time points up to 90 days after stroke. Researchers will assess functional outcomes, neurological changes, and safety measures, including the risk of intracranial hemorrhage. The total follow-up period extends to 90 days post-stroke.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of a half-dose bolus of recombinant staphylokinase r-SAK given before primary percutaneous coronary intervention PCI in patients with acute ST-segment elevation myocardial infarction STEMI. This phase 4, multi-center, randomized, double-blind, placebo-controlled trial aims to determine whether adding r-SAK immediately before PCI improves outcomes compared to placebo within 120 minutes of the procedure. The study is motivated by the need to improve early reperfusion and reduce heart damage in STEMI patients. Participants are randomly assigned to receive either a single intravenous bolus of 5 mg r-SAK over 3 minutes or a placebo injection within 10 minutes after STEMI diagnosis and before PCI. The trial compares these two groups to assess the impact on major adverse cardiovascular events MACE within 90 days. The study also monitors other heart and brain event outcomes, heart function measures, and blood flow grades before and after PCI. During the study, participants undergo assessments including cardiac magnetic resonance imaging, echocardiograms, and blood tests for heart-related biomarkers at specified days up to 360 days after treatment. Researchers observe the occurrence of cardiovascular events, measure heart function, and monitor safety outcomes throughout the trial period. Participants are followed to evaluate both short-term and longer-term effects of the treatment compared to placebo.
Actively Recruiting
Researchers are evaluating the efficacy and safety of BAT5906 compared to Lucentis in people with diabetic macular edema DME. This multicenter, randomized, double-blind trial plans to enroll 406 participants aged 18 to 80 years who have DME affecting the central part of the retina. The primary goal is to assess changes in best-corrected visual acuity BCVA from the start of the study to week 52 using the ETDRS chart. Participants are randomly assigned to receive either BAT5906 or Lucentis through intravitreal injections directly into the eye. Each treatment is given once every 4 weeks for three doses, followed by monitoring visits every 4 weeks with possible additional doses as needed, continuing through week 52. BAT5906 is administered at 4.0 mg per eye, while Lucentis is given at 0.5 mg per eye. Throughout the study, participants undergo regular eye exams, safety assessments, and blood tests to monitor immune response. Researchers measure visual acuity changes to determine treatment effects. The study includes ongoing safety monitoring and assessments until week 52 to evaluate both treatments effectiveness and safety in managing DME.
Actively Recruiting
Researchers are evaluating the combination of vebreltinib and furmonertinib in patients with locally advanced or metastatic non-small cell lung cancer NSCLC who have c-Met amplification and have experienced failure of prior EGFR-TKI treatment. This study includes both a Phase Ib and a Phase II clinical trial. The Phase Ib study aims to determine the maximum tolerated dose MTD, dose-limiting toxicities DLT, and the recommended Phase II dose RP2D of vebreltinib combined with furmonertinib. The Phase II study will assess the efficacy of this combination by measuring outcomes such as overall response rate ORR and progression-free survival PFS. The Phase Ib study involves two stages dose escalation and dose expansion. Dose escalation uses a 33 design with vebreltinib doses of 100 mg, 150 mg, and 200 mg taken twice daily, combined with furmonertinib at 80 mg once daily. Dose escalation decisions depend on the occurrence of DLTs within 28 days. The dose expansion stage will enroll approximately 10 additional patients per selected dose level to confirm safety and determine the recommended dose for Phase II. In the Phase II study, participants will receive the recommended dose of vebreltinib twice daily along with furmonertinib 80 mg once daily until disease progression or intolerable side effects occur. During the study, participants will undergo various assessments including tumor evaluations based on RECIST v1.1 criteria, laboratory tests, and safety monitoring. The primary outcomes include incidence of DLTs, determination of MTD and RP2D in Phase Ib, and ORR in Phase II. Secondary outcomes include progression-free survival, duration of response, disease control rate, overall survival, adverse events, and health-related quality of life. The total observation period for some outcomes extends up to five years, with active treatment continuing until disease progression or unacceptable toxicity.
Actively Recruiting
Researchers are evaluating XNW28012, a drug being studied for treatment in patients with metastatic pancreatic ductal carcinoma who have not responded to or cannot tolerate two prior standard treatments. This phase III, randomized, double-blind, multicenter study compares XNW28012 against a placebo mimetic, both given alongside optimal supportive care including nutritional support and pain management. Participants are randomly assigned in a 21 ratio to receive either XNW28012 at a dose of 2.4 mgkg every three weeks or the placebo mimetic on the same schedule. Both groups receive best supportive care throughout the study. The treatment period continues while monitoring responses and safety. The study includes comprehensive evaluation of disease progression and treatment effects over an average of two years. During the study, participants undergo regular assessments including imaging and laboratory tests to evaluate tumor response, disease control, and adverse events. Researchers measure survival time from enrollment until death from any cause, along with progression-free survival and other response-related outcomes. Safety monitoring includes tracking adverse events and drug antibody levels. Participants remain in the study for about two years on average, with follow-up to collect outcome data.
Actively Recruiting
Researchers are evaluating early minimally invasive surgery with thrombolysis eMIST compared to the best medical management in patients with acute spontaneous supratentorial intracerebral hemorrhage ICH of 20 mL or more. This multicenter, randomized, adaptive clinical trial aims to improve functional outcomes after stroke caused by this type of brain hemorrhage. The trial uses a prospective, open-label design with blinded assessment of results and includes adaptive sample size estimation based on interim follow-up data. Participants are randomly assigned to receive either early minimally invasive catheter evacuation followed by up to ten doses of urokinase to dissolve the clot, or the best available standard medical care without surgery. The urokinase doses are administered through a catheter placed directly into the hemorrhage site, aiming for clot resolution. The randomized intervention must start within specific timing windows after stroke onset to be included. During the study, participants undergo assessments including head CT scans, functional evaluations using the utility-weighted modified Rankin Scale at multiple time points up to 180 days, and other measures such as quality of life and daily living activities. Safety and efficacy are monitored throughout the trial, which lasts until study completion in 2028. Researchers focus on functional improvement as the primary outcome, with additional secondary measurements including mortality and clot removal at defined times.